News | March 25, 2013

Hip Replacement Reduces Heart Failure, Depression and Diabetes Risk

Study supports the value of THR in aiding long-term health at minimal cost

March 25, 2013 — In addition to improving life quality and diminishing pain, total hip replacement (THR) is associated with reduced mortality, heart failure, depression and diabetes rates in Medicare patients with osteoarthritis, according to a new study presented at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). The procedure also is cost effective with the seven-year costs of THR only $6,366 higher than the cost of treating an osteoarthritis patient for hip pain without THR.

"The study has demonstrated that THR confers a potential long-term benefit in terms of prolonged lifespan and reduced burden of disease in Medicare patients with osteoarthritis of the hip," said lead study author Scott Lovald, Ph.D., a researcher at Exponent Inc.

While the short-term benefits of THR are well known and documented, less information exists on the long-term effects, cost and value of the surgery.

Using Medicare codes, researchers identified more than 43,000 patients with osteoarthritis of the hip from 1998 to 2009. These patients were divided into two groups — those receiving THR and those not receiving THR. The researchers followed all of the patients for at least one year, and nearly 24,000 for seven years, looking at annual Medicare payments, mortality, new diagnoses of congestive heart failure, ischemic heart disease, artherosclerosis (hardening and narrowing of the arteries), diabetes and depression. The data was adjusted for differences in age, sex, race, buy-in status, region and Charlson score (standard quantification of the number and severity of comorbidities a patient presents with).

Among the results:

  • The THR patients had a consistently lower mortality risk – less than 52 percent of that in the non-THR group.
  • Heart failure was similar between groups in the first year, but there was a consistent reduced risk (risk was between 0.85 and 0.92 of the risk for the non-THR group) at three-to-seven years following surgery.
  • THR patients had a reduced risk of diabetes at one and three years.
  • THR patients had a reduced rate of depression starting at three years post THR surgery.

 

The THR patients in the study did have an increased risk of ischemic heart disease and atherosclerosis at one year, and an increased risk of "cardiovascular disease unspecified" over all time points.

The seven-year cumulative average Medicare payment for all medical care was $82,788 for non-THR patients and $89,154 for THR patients, for a difference of $6,366. The actual average per-patient THR cost is expected to be much less than $6,366 when differences in costs incurred due to prescription pain medications are taken into account.

"Joint (replacement) has been proposed as possibly cost-saving in the management of disability related to arthritis," said Lovald. "This study provides supporting data to evaluate the cost-effectiveness of THR."

For more information: Orthoinfo.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init